stockrowiRhythm Holdings, Inc.
IRTC Healthcare Medical Devices
iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
- Revenue
- +14.9%
- EPS
- −462.5%
- Free cash flow
- −157.6%
- Total debt
- +0.48%
Quarter to September 2026, against a year earlier
Follow IRTC
Alert me
iRhythm Holdings, Inc. (IRTC) EPS (diluted)
iRhythm Holdings, Inc.'s EPS (diluted) for fiscal 2025 was −$1.39, compared with −$3.63 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.17. Over the past ten years it has ranged from −$16.57 (fiscal 2015) to −$1.30 (fiscal 2017); the current reading is higher than 91% of that period. iRhythm Holdings, Inc. ranks 88th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.39 | — |
| FY2024 | −$3.63 | — |
| FY2023 | −$4.04 | — |
| FY2022 | −$3.88 | — |
| FY2021 | −$3.46 | — |
| FY2020 | −$1.58 | — |
| FY2019 | −$2.16 | — |
| FY2018 | −$2.02 | — |
| FY2017 | −$1.30 | — |
| FY2016 | −$3.95 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.90 | — |
| Jun 2026 | −$0.01 | — |
| Mar 2026 | −$0.43 | — |
| Dec 2025 | $0.17 | — |
| 40 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UFPT UFP Technologies, Inc. compare | $9.81 |
| TMDX TransMedics Group, Inc. compare | $3.69 |
| LIVN LivaNova PLC compare | $3.49 |
| ITGR Integer Holdings Corporation compare | $2.98 |
| HAE Haemonetics Corporation compare | $2.23 |
| NEOG Neogen Corporation compare | −$0.25 |
| TXG 10x Genomics compare | −$0.59 |
| AXGN AxoGen, Inc. compare | −$0.65 |
| IRTC iRhythm Holdings, Inc. | −$1.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on IRTC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement